BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 15674929)

  • 1. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
    Norris SL; Zhang X; Avenell A; Gregg E; Schmid CH; Lau J
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004096. PubMed ID: 15674929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.
    Norris SL; Zhang X; Avenell A; Gregg E; Schmid CH; Kim C; Lau J
    Arch Intern Med; 2004 Jul; 164(13):1395-404. PubMed ID: 15249348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interventions for the treatment of obesity in children and adolescents.
    Mead E; Atkinson G; Richter B; Metzendorf MI; Baur L; Finer N; Corpeleijn E; O'Malley C; Ells LJ
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012436. PubMed ID: 27899001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY; Thomas GN; Chan JC; Tomlinson B
    Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.
    Padwal R; Li SK; Lau DC
    Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1437-46. PubMed ID: 12975638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E; Martín Folgueras T
    Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: pharmacologic treatment of obesity.
    Li Z; Maglione M; Tu W; Mojica W; Arterburn D; Shugarman LR; Hilton L; Suttorp M; Solomon V; Shekelle PG; Morton SC
    Ann Intern Med; 2005 Apr; 142(7):532-46. PubMed ID: 15809465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A; Horvath K; Jeitler K; Berghold A; Stich AK; Matyas E; Pignitter N; Siering U
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007654. PubMed ID: 19588440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.
    Douglas IJ; Bhaskaran K; Batterham RL; Smeeth L
    Br J Clin Pharmacol; 2015 Jun; 79(6):1020-7. PubMed ID: 25641659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Siering U; Semlitsch T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007654. PubMed ID: 23543553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
    Ara R; Blake L; Gray L; Hernández M; Crowther M; Dunkley A; Warren F; Jackson R; Rees A; Stevenson M; Abrams K; Cooper N; Davies M; Khunti K; Sutton A
    Health Technol Assess; 2012; 16(5):iii-xiv, 1-195. PubMed ID: 22340890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
    Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
    Halford JC
    Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.